Selparcatinib as monotherapy is indicated for the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||08/06/2021|
|Rapid review completed||29/06/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care.|